The addition of hormonal therapy to radiation therapy improves survival inmenwith unfavourable risk prostate cancer.Yet,menwith prostate cancer have higher rates of non-cancer death than the general population andmost will die fromcauses other than their indexmalignancy. [more]
Early aggressive treatment in patients whose cancer is likely to progress slowly, if at all, causes side-effects and reduces their quality of life for no benefit. Can active surveillance avoid this? Download full article
A recent study has shown that treatment interruptions during a fractionated external-beam radiotherapy course for localised prostate cancers may have a negative effect on patient outcome. Limiting or modifying the overall elapsed time between treatments [more]
First results of randomised clinical screening trials are traditionally met with a barrage of comments by opinionated observers, and the back-to-back publication in the March 26 issue of the New England Journal of Medicine on [more]
Selected repor ts edited by Janet Fricker Download full article
Hormonal treatment remains a main stay of systemic therapy for prostate cancer despite recent developments in chemotherapy and intensive research with targeted drugs and immunotherapy. Its efficacy in palliative management of advanced disease has prompted [more]
Selected reports edited by Janet Fricker Download full article
Selected reports edited by Janet Fricker Download full article
Selected reports edited by Janet Fricker Download full article
Selected reports edited by Hannah Brown Download full article
Selected reports edited by Hannah Brown Download full article
Selected press reports complied by the ESO Cancer Media Centre Download full article
In prostate cancer, a trial comparing conventional- versus high-dose conformal radiotherapy has shown that increasing the dose can improve outcome, with only slight increases in toxicity. Download full article